IMMUNOCARD STAT! RSV MODEL #750630

K041445 · Meridian Bioscience, Inc. · GQG · Aug 13, 2004 · Microbiology

Device Facts

• Record ID: K041445
• Device Name: IMMUNOCARD STAT! RSV MODEL #750630
• Applicant: Meridian Bioscience, Inc.
• Product Code: GQG · Microbiology
• Decision Date: Aug 13, 2004
• Decision: SESE
• Submission Type: Traditional
• Regulation: 21 CFR 866.3480
• Device Class: Class 1
• Attributes: Pediatric

Indications for Use

ImmunoCard STAT!® RSV is a rapid, qualitative, lateral-flow immunoassay for the detection of Respiratory Syncytial Virus (RSV) antigens (fusion protein or internal protein) in human Nasal Wash, Nasopharyngeal Aspirate and Nasal and Nasopharyngeal Swab Samples. It is designed to test specimens from symptomatic neonatal and pediatric patients. It is recommended that all negative test results be confirmed by cell culture.

Device Story

Rapid, qualitative, lateral-flow immunochromatographic test; detects RSV fusion or internal proteins in nasal/nasopharyngeal samples. Sample diluted in buffer; applied to device port; antigen binds to monoclonal antibody-colloidal gold conjugate. Complexes captured by anti-RSV antibodies on assay membrane; visible pink-red line indicates positive result. Used in clinical settings; performed by healthcare professionals. Provides rapid diagnostic information to assist in clinical management of symptomatic pediatric patients. Negative results require confirmation by cell culture.

Clinical Evidence

Performance evaluated via method comparison against cell culture across three independent labs using fresh and frozen samples. Fresh wash/aspirate (n=29): 77.8% sensitivity, 75.0% specificity. Fresh swab (n=54): 78.9% sensitivity, 100% specificity. Frozen wash/aspirate (n=19): 84.2% sensitivity. Frozen swab (n=72): 94.4% sensitivity, 94.4% specificity. Analytical sensitivity (LOD) ranged from 10 to 10,000 TCID50/mL. Analytical specificity confirmed against various bacterial, viral, and yeast strains.

Technological Characteristics

Lateral-flow immunochromatographic assay; utilizes monoclonal antibodies specific for RSV fusion and internal proteins; colloidal gold conjugate detection; visual readout (pink-red line); manual test format; no instrumentation required.

Indications for Use

Indicated for the qualitative detection of RSV antigens in human nasal wash, nasopharyngeal aspirate, and nasal/nasopharyngeal swab samples from symptomatic neonatal and pediatric patients. Negative results should be confirmed by cell culture.

Regulatory Classification

Identification

Respiratory syncytial virus serological reagents are devices that consist of antigens and antisera used in serological tests to identify antibodies to respiratory syncytial virus in serum. Additionally, some of these reagents consist of respiratory syncytial virus antisera conjugated with a fluorescent dye (immunofluorescent reagents) and used to identify respiratory syncytial viruses from clinical specimens or from tissue culture isolates derived from clinical specimens. The identification aids in the diagnosis of respiratory syncytial virus infections and provides epidemiological information on diseases caused by these viruses. Respiratory syncytial viruses cause a number of respiratory tract infections, including the common cold, pharyngitis, and infantile bronchopneumonia.

Predicate Devices

• Binax NOW® RSV (k032166)

Submission Summary (Full Text)

{0}

Page 1 of 5

# 510(k) SUBSTANTIAL EQUIVALENCE DETERMINATION DECISION SUMMARY

A. 510(k) Number: k041445
B. Purpose for Submission: New device
C. Analyte: Respiratory Syncytial Virus (RSV) antigens
D. Type of Test: Immunochromatographic test
E. Applicant: Meridian Bioscience, Inc.
F. Proprietary and Established Names: ImmunoCard STAT!® RSV

## G. Regulatory Information:

1. Regulation section: 866.3480; RSV serological reagents
2. Classification: Class: I
3. Product Code: GQG; Antigens, CF, Respiratory Syncytial Virus
4. Panel: 83 Microbiology

## H. Intended Use:

1. Intended use(s):
ImmunoCard STAT!® RSV is a rapid, qualitative, lateral-flow immunoassay for the detection of Respiratory Syncytial Virus (RSV) antigens (fusion protein or internal protein) in human Nasal Wash, Nasopharyngeal Aspirate and Nasal and Nasopharyngeal Swab Samples. It is designed to test specimens from symptomatic neonatal and pediatric patients. It is recommended that all negative test results be confirmed by cell culture.

2. Indication(s) for use:
ImmunoCard STAT! RSV is a rapid, qualitative, lateral-flow immunoassay for the detection of Respiratory Syncytial Virus (RSV) antigens (fusion protein or internal protein) in human nasal wash, nasopharyngeal aspirate and nasal and nasopharyngeal swab samples. It is designed to test specimens from symptomatic neonatal and pediatric patients. It is recommended that all negative test results be confirmed by cell culture.

3. Special condition for use statement(s): For prescription use
4. Special instrument Requirements: None

{1}

Page 2 of 5

# I. Device Description:

ImmunoCard STAT! RSV uses monoclonal antibodies specific for the RSV fusion protein and an RSV internal protein as both the capture and detection antibodies. Nasal samples from wash, aspirate or swab are added to Sample Diluent Buffer using the transfer pipette provided with the kit. The diluted sample (approximately 1 in 2 dilution) is added to the sample port of the device. RSV fusion protein or internal protein antigen in the diluted sample binds to the corresponding monoclonal antibody-colloidal gold conjugate as the sample moves through the device. The antigen-antibody-colloidal gold complexes are captured by anti-RSV fusion protein and/or anti-RSV internal protein bound to the assay membrane at the test position of the device central window yielding a visible pink-red line.

# J. Substantial Equivalence Information:

1. Predicate device name(s): Binax NOW® RSV
2. Predicate K number(s): k032166
3. Comparison with predicate:

| Similarities | | |
| --- | --- | --- |
| Item | Device | Predicate |
| Method and type | Immunochromatography
Rapid test
Qualitative | Immunochromatography
Rapid test
Qualitative |
| Differences | | |
| Item | Device | Predicate |
| Specimen Type | Nasal Wash,
Nasopharyngeal Aspirate
and
Nasal Swab and
Nasopharyngeal Swab | Nasal wash |

K. Standard/Guidance Document Referenced (if applicable): Not applicable

L. Test Principle: Immunochromatography

M. Performance Characteristics (if/when applicable):

1. Analytical performance:

a. Precision/Reproducibility: The reproducibility of ImmunoCard STAT! RSV was determined using two panels of known negative (n = 2), positive (n = 5) and LOD (n = 1) samples that were coded and

{2}

Page 3 of 5

randomly sorted to prevent their identities. Two of the five positive samples were weakly reactive. Each reproducibility panel was tested on three consecutive days by three independent test sites. Test results with one positive sample were reproducible at the rate of 94%. All other samples tested produced the expected results 100% of the time.

b. Linearity/assay reportable range: Not applicable

c. Traceability, Stability, Expected values (controls, calibrators, or method): Not applicable

d. Detection limit: The analytical sensitivity of this assay was established in tests with dilutions of three examples each of RSV strains A (VR-1540, VR-1302, VR-26) and B (VR-1401, VR-1400, VR-955). The lower limit of detection with these strains ranged from 10 to 10,000 virions/mL (TCID₅₀/mL).

e. Analytical specificity: The specificity of ImmunoCard STAT! RSV was tested utilizing a number of bacterial, viral and yeast strains. Positive and negative respiratory specimens were spiked with ≥ 7.5 X 10⁷/mL bacteria or yeast. Virus inoculations were performed at ≥ 1500 TCID₅₀ or CEID₅₀/mL. None of the microorganisms tested yielded a positive result in the RSV-negative sample or interfered with detection of the RSV-positive sample. Both the negative and positive respiratory samples were positive when spiked with RSV A strain VR-26.

f. Assay cut-off: Not applicable

2. Comparison studies:

a. Method comparison with predicate device:

Three independent laboratories tested ImmunoCard STAT! RSV with samples from neonatal and pediatric patients that were characterized using cell culture. The specimens were tested either fresh or frozen.

Prospective samples:

| | | ICS RSV | |
| --- | --- | --- | --- |
| Fresh samples – Wash/Aspirate | Pos | Neg | Total |
| Tissue Culture Pos | 7 | 2 | 9 |
| Tissue Culture Neg | 5 | 15 | 20 |
| Total | 12 | 17 | 29 |

Agreement 22/29 (75.9%)
Sensitivity 7/9 (77.8%)
Specificity 15/20 (75.0%)
Predictive value positive test 7/12 (58.3%)

{3}

Page 4 of 5

Predictive value negative test 15/17 (88.2%)

| | | ICS RSV | |
| --- | --- | --- | --- |
| Fresh samples – Swab | Pos | Neg | Total |
| Tissue Culture Pos | 15 | 4 | 19 |
| Tissue Culture Neg | 0 | 35 | 35 |
| Total | 15 | 39 | 54 |

Agreement 50/54 (92.6%)
Sensitivity 15/19 (78.9%)
Specificity 35/35 (100%)
Predictive value positive test 15/15 (100%)
Predictive value negative test 35/39 (89.7%)

## Archived samples:

| | | ICS RSV | |
| --- | --- | --- | --- |
| Frozen samples– Wash/Aspirate | Pos | Neg | Total |
| Tissue Culture Pos | 16 | 3 | 19 |
| Tissue Culture Neg | 0 | 0 | 0 |
| Total | 16 | 3 | 19 |

Agreement 16/19 (84.2%)
Sensitivity 16/19 (84.2%)
Specificity 0/0 (0%)
Predictive value positive test 16/16 (100%)
Predictive value negative test 0/3 (0%)

| | | ICS RSV | |
| --- | --- | --- | --- |
| Frozen samples – Swab | Pos | Neg | Total |
| Tissue Culture Pos | 17 | 1 | 18 |
| Tissue Culture Neg | 3 | 51 | 54 |
| Total | 20 | 52 | 72 |

Agreement 68/72 (94.4%)
Sensitivity 17/18 (94.4%)
Specificity 51/54 (94.4%)
Predictive value positive test 17/20 (85.0%)
Predictive value negative test 51/52 (98.1%)

## b. Matrix comparison: Not applicable

### 3. Clinical studies:

#### a. Clinical sensitivity: Not applicable

{4}

Page 5 of 5

b. Clinical specificity: Not applicable

c. Other clinical supportive data (when a and b are not applicable): Not applicable

4. Clinical cut-off: Not applicable

5. Expected values/Reference range: Not applicable

N. Conclusion:

The submitted information in this premarket notification is complete and supports a substantial equivalence decision.